NYSE:MYOV - Myovant Sciences Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $19.91 -0.39 (-1.92 %) (As of 07/20/2018 04:00 PM ET)Previous Close$20.30Today's Range$19.90 - $20.5152-Week Range$9.92 - $25.54Volume68,100 shsAverage Volume80,144 shsMarket Capitalization$1.31 billionP/E Ratio-8.26Dividend YieldN/ABeta-2.06 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd. Receive MYOV News and Ratings via Email Sign-up to receive the latest news and ratings for MYOV and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNYSE:MYOV CUSIPN/A Webwww.myovant.com Phone203-318-9709 Debt Debt-to-Equity Ratio1.16 Current Ratio3.09 Quick Ratio3.09 Price-To-Earnings Trailing P/E Ratio-8.26 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$0.62 per share Price / Book32.11 Profitability EPS (Most Recent Fiscal Year)($2.41) Net IncomeN/A Net MarginsN/A Return on Equity-148.99% Return on Assets-102.95% Miscellaneous Employees86 Outstanding Shares64,880,000Market Cap$1,312.42 Myovant Sciences (NYSE:MYOV) Frequently Asked Questions What is Myovant Sciences' stock symbol? Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV." How were Myovant Sciences' earnings last quarter? Myovant Sciences Ltd (NYSE:MYOV) announced its quarterly earnings data on Tuesday, June, 12th. The company reported ($0.81) EPS for the quarter, missing the Zacks' consensus estimate of ($0.77) by $0.04. View Myovant Sciences' Earnings History. When is Myovant Sciences' next earnings date? Myovant Sciences is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Myovant Sciences. What price target have analysts set for MYOV? 6 analysts have issued twelve-month price targets for Myovant Sciences' shares. Their forecasts range from $18.00 to $44.00. On average, they anticipate Myovant Sciences' share price to reach $26.75 in the next year. This suggests a possible upside of 34.4% from the stock's current price. View Analyst Ratings for Myovant Sciences. What is the consensus analysts' recommendation for Myovant Sciences? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Myovant Sciences stock? Here are some recent quotes from research analysts about Myovant Sciences stock: 1. According to Zacks Investment Research, "Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda. " (7/17/2018) 2. Cowen Inc analysts commented, "Myovant reported a FQ2:18 net loss of $29.9MM and a 9/30 cash balance of." (11/14/2017) Who are some of Myovant Sciences' key competitors? Some companies that are related to Myovant Sciences include GALAPAGOS NV/S (GLPG), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals (GWPH), Madrigal Pharmaceuticals (MDGL), Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), Amicus Therapeutics (FOLD), The Medicines (MDCO) and Horizon Pharma (HZNP). Who are Myovant Sciences' key executives? Myovant Sciences' management team includes the folowing people: Dr. Lynn Seely, Chief Exec. Officer, Pres and Exec. Director (Age 59)Mr. Frank L. Karbe, Principal Financial & Accounting Officer (Age 50)Ms. Marianne L. Romeo, Head of Global Transactions & Risk Management (Age 50)Ms. Julie Tran MBA, MSHR, VP of HRMr. Bryan Selby, Sr. VP of Product Devel. When did Myovant Sciences IPO? (MYOV) raised $176 million in an initial public offering (IPO) on Thursday, October 27th 2016. The company issued 13,000,000 shares at a price of $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers. Has Myovant Sciences been receiving favorable news coverage? Media stories about MYOV stock have trended somewhat positive this week, according to Accern. Accern identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Myovant Sciences earned a media sentiment score of 0.16 on Accern's scale. They also gave news headlines about the company an impact score of 46.25 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. Who are Myovant Sciences' major shareholders? Myovant Sciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Matisse Capital (0.02%). Company insiders that own Myovant Sciences stock include Holdings Ltd Dexxon and Pharmaceuticals Interna Takeda. View Institutional Ownership Trends for Myovant Sciences. Which institutional investors are buying Myovant Sciences stock? MYOV stock was bought by a variety of institutional investors in the last quarter, including Matisse Capital. Company insiders that have bought Myovant Sciences stock in the last two years include Holdings Ltd Dexxon and Pharmaceuticals Interna Takeda. View Insider Buying and Selling for Myovant Sciences. How do I buy shares of Myovant Sciences? Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Myovant Sciences' stock price today? One share of MYOV stock can currently be purchased for approximately $19.91. How big of a company is Myovant Sciences? Myovant Sciences has a market capitalization of $1.31 billion. Myovant Sciences employs 86 workers across the globe. How can I contact Myovant Sciences? Myovant Sciences' mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The company can be reached via phone at 203-318-9709 or via email at [email protected] MarketBeat Community Rating for Myovant Sciences (NYSE MYOV)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 110 (Vote Outperform)Underperform Votes: 104 (Vote Underperform)Total Votes: 214MarketBeat's community ratings are surveys of what our community members think about Myovant Sciences and other stocks. Vote "Outperform" if you believe MYOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: What does earnings per share mean?